JP2020152735A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020152735A5 JP2020152735A5 JP2020110083A JP2020110083A JP2020152735A5 JP 2020152735 A5 JP2020152735 A5 JP 2020152735A5 JP 2020110083 A JP2020110083 A JP 2020110083A JP 2020110083 A JP2020110083 A JP 2020110083A JP 2020152735 A5 JP2020152735 A5 JP 2020152735A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- antibody
- cancer
- variable region
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090001123 antibodies Proteins 0.000 claims 21
- 102000004965 antibodies Human genes 0.000 claims 21
- 125000003275 alpha amino acid group Chemical group 0.000 claims 20
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 239000000427 antigen Substances 0.000 claims 15
- 108091007172 antigens Proteins 0.000 claims 15
- 102000038129 antigens Human genes 0.000 claims 15
- 201000011510 cancer Diseases 0.000 claims 11
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 8
- 125000000539 amino acid group Chemical group 0.000 claims 6
- 239000000611 antibody drug conjugate Substances 0.000 claims 6
- 108091008116 antibody drug conjugates Proteins 0.000 claims 6
- 206010005003 Bladder cancer Diseases 0.000 claims 4
- 210000004408 Hybridomas Anatomy 0.000 claims 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 2
- 230000000875 corresponding Effects 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- NFGXHKASABOEEW-UHFFFAOYSA-N (+)-methoprene Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 1
- 230000035693 Fab Effects 0.000 claims 1
- DASWEROEPLKSEI-UIJRFTGLSA-N Monomethyl auristatin E Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)C1=CC=CC=C1 DASWEROEPLKSEI-UIJRFTGLSA-N 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 210000004881 tumor cells Anatomy 0.000 claims 1
Claims (28)
- SEQ ID NO:7に示された3つの相補性決定領域(CDR)のアミノ酸配列を含む該3つのCDRを含む重鎖可変領域と、SEQ ID NO:8に示された3つのCDRのアミノ酸配列を含む該3つのCDRを含む軽鎖可変領域とを含む、抗191P4D12抗体またはその抗原結合フラグメントであって、該CDRが、Kabat、Chothia、IMGT、またはContactナンバリングスキームによって決定される、抗体またはその抗原結合フラグメント。
- SEQ ID NO:7の45〜52の範囲のアミノ酸配列からなる重鎖可変領域相補性決定領域1(CDRH1)、SEQ ID NO:7の70〜77の範囲のアミノ酸配列からなるCDRH2、SEQ ID NO:7の116〜125の範囲のアミノ酸配列からなるCDRH3、SEQ ID NO:8の49〜54の範囲のアミノ酸配列からなる軽鎖可変領域相補性決定領域1(CDRL1)、SEQ ID NO:8の72〜74の範囲のアミノ酸配列からなるCDRL2、およびSEQ ID NO:8の111〜119の範囲のアミノ酸配列からなるCDRL3を含む、請求項1記載の抗体またはその抗原結合フラグメント。
- SEQ ID NO:7に示された重鎖可変領域アミノ酸配列と少なくとも80%相同のアミノ酸配列を含む重鎖可変領域と、SEQ ID NO:8に示された軽鎖可変領域アミノ酸配列と少なくとも80%相同のアミノ酸配列を含む軽鎖可変領域とを含み、かつCDRH1、CDRH2、CDRH3、CDRL1、CDRL2、およびCDRL3の配列が請求項2の対応する配列と同一である、請求項2記載の抗体またはその抗原結合フラグメント。
- SEQ ID NO:7に示された重鎖可変領域アミノ酸配列と少なくとも85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%または99%相同のアミノ酸配列を含む重鎖可変領域と、SEQ ID NO:8に示された軽鎖可変領域アミノ酸配列と少なくとも85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%または99%相同のアミノ酸配列を含む軽鎖可変領域とを含み、かつCDRH1、CDRH2、CDRH3、CDRL1、CDRL2、およびCDRL3の配列が請求項2の対応する配列と同一である、請求項2または3記載の抗体またはその抗原結合フラグメント。
- 重鎖可変領域が、SEQ ID NO:7のアミノ酸残基20〜アミノ酸残基136を含み、軽鎖可変領域が、SEQ ID NO:8のアミノ酸残基23〜アミノ酸残基130を含む、請求項1〜4のいずれか一項記載の抗体またはその抗原結合フラグメント。
- 抗体が、SEQ ID NO:7のアミノ酸残基20〜アミノ酸残基466を含む重鎖およびSEQ ID NO:8のアミノ酸残基23〜アミノ酸残基236を含む軽鎖を含む、請求項1〜5のいずれか一項記載の抗体。
- American Type Culture Collection(ATCC)アクセッション番号PTA-11267で寄託されたハイブリドーマによって産生された抗体の重鎖可変領域のアミノ酸配列を含む重鎖可変領域、およびATCCアクセッション番号PTA-11267で寄託されたハイブリドーマによって産生された抗体の軽鎖可変領域のアミノ酸配列を含む軽鎖可変領域を含む、抗体またはその抗原結合フラグメント。
- 抗体が、ATCCアクセッション番号PTA-11267で寄託されたハイブリドーマによって産生された抗体の重鎖のアミノ酸配列を含む重鎖、およびATCCアクセッション番号PTA-11267で寄託されたハイブリドーマによって産生された抗体の軽鎖のアミノ酸配列を含む軽鎖を含む、請求項7記載の抗体。
- 抗原結合フラグメントが、Fab、F(ab') 2 、Fv、またはscFvである、請求項1〜5および7のいずれか一項記載の抗体またはその抗原結合フラグメント。
- 完全ヒト抗体またはその抗原結合フラグメントである、請求項1〜9のいずれか一項記載の抗体またはその抗原結合フラグメント。
- pが約4である、請求項11記載の抗体薬物結合体。
- 治療的有効量の請求項1〜10のいずれか一項記載の抗体またはその抗原結合フラグメント、または治療的有効量の請求項11または12記載の抗体薬物結合体、および薬学的に許容可能な賦形剤を含む、薬学的組成物。
- 抗体薬物結合体におけるp値が約3.8である、請求項13記載の薬学的組成物。
- 対象の癌を予防または治療するための、請求項13または14記載の薬学的組成物。
- 癌が191P4D12を発現する腫瘍細胞を含む、請求項15記載の薬学的組成物。
- 対象がヒト対象である、請求項15または16記載の薬学的組成物。
- 癌が、結腸癌、卵巣癌、食道癌、頭頚部癌、膵臓癌、肺癌、膀胱癌、または乳癌である、請求項15〜17のいずれか一項記載の薬学的組成物。
- 癌が膵臓癌である、請求項18記載の薬学的組成物。
- 癌が肺癌である、請求項18記載の薬学的組成物。
- 癌が膀胱癌である、請求項18記載の薬学的組成物。
- 癌が乳癌である、請求項18記載の薬学的組成物。
- 癌が結腸癌である、請求項18記載の薬学的組成物。
- 癌が卵巣癌である、請求項18記載の薬学的組成物。
- 癌が食道癌である、請求項18記載の薬学的組成物。
- 癌が頭頚部癌である、請求項18記載の薬学的組成物。
- 放射線または化学療法剤と組み合わせて投与される、請求項18〜26のいずれか一項記載の薬学的組成物。
- 膀胱癌が進行した膀胱癌である、請求項21記載の薬学的組成物。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022039841A JP7370405B2 (ja) | 2010-09-29 | 2022-03-15 | 191p4d12タンパク質に結合する抗体薬物結合体(adc) |
JP2023178591A JP2023179713A (ja) | 2010-09-29 | 2023-10-17 | 191p4d12タンパク質に結合する抗体薬物結合体(adc) |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38793310P | 2010-09-29 | 2010-09-29 | |
US61/387,933 | 2010-09-29 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018207426A Division JP6726258B2 (ja) | 2010-09-29 | 2018-11-02 | 191p4d12タンパク質に結合する抗体薬物結合体(adc) |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022039841A Division JP7370405B2 (ja) | 2010-09-29 | 2022-03-15 | 191p4d12タンパク質に結合する抗体薬物結合体(adc) |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2020152735A JP2020152735A (ja) | 2020-09-24 |
JP2020152735A5 true JP2020152735A5 (ja) | 2020-12-03 |
JP7042872B2 JP7042872B2 (ja) | 2022-03-28 |
Family
ID=45871300
Family Applications (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013531875A Active JP6083871B2 (ja) | 2010-09-29 | 2011-09-29 | 191p4d12タンパク質に結合する抗体薬物結合体(adc) |
JP2016243252A Withdrawn JP2017110002A (ja) | 2010-09-29 | 2016-12-15 | 191p4d12タンパク質に結合する抗体薬物結合体(adc) |
JP2018207426A Active JP6726258B2 (ja) | 2010-09-29 | 2018-11-02 | 191p4d12タンパク質に結合する抗体薬物結合体(adc) |
JP2018207044A Pending JP2019055958A (ja) | 2010-09-29 | 2018-11-02 | 191p4d12タンパク質に結合する抗体薬物結合体(adc) |
JP2018207295A Pending JP2019031563A (ja) | 2010-09-29 | 2018-11-02 | 191p4d12タンパク質に結合する抗体薬物結合体(adc) |
JP2020110083A Active JP7042872B2 (ja) | 2010-09-29 | 2020-06-26 | 191p4d12タンパク質に結合する抗体薬物結合体(adc) |
JP2022039841A Active JP7370405B2 (ja) | 2010-09-29 | 2022-03-15 | 191p4d12タンパク質に結合する抗体薬物結合体(adc) |
JP2023178591A Pending JP2023179713A (ja) | 2010-09-29 | 2023-10-17 | 191p4d12タンパク質に結合する抗体薬物結合体(adc) |
Family Applications Before (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013531875A Active JP6083871B2 (ja) | 2010-09-29 | 2011-09-29 | 191p4d12タンパク質に結合する抗体薬物結合体(adc) |
JP2016243252A Withdrawn JP2017110002A (ja) | 2010-09-29 | 2016-12-15 | 191p4d12タンパク質に結合する抗体薬物結合体(adc) |
JP2018207426A Active JP6726258B2 (ja) | 2010-09-29 | 2018-11-02 | 191p4d12タンパク質に結合する抗体薬物結合体(adc) |
JP2018207044A Pending JP2019055958A (ja) | 2010-09-29 | 2018-11-02 | 191p4d12タンパク質に結合する抗体薬物結合体(adc) |
JP2018207295A Pending JP2019031563A (ja) | 2010-09-29 | 2018-11-02 | 191p4d12タンパク質に結合する抗体薬物結合体(adc) |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022039841A Active JP7370405B2 (ja) | 2010-09-29 | 2022-03-15 | 191p4d12タンパク質に結合する抗体薬物結合体(adc) |
JP2023178591A Pending JP2023179713A (ja) | 2010-09-29 | 2023-10-17 | 191p4d12タンパク質に結合する抗体薬物結合体(adc) |
Country Status (29)
Country | Link |
---|---|
US (8) | US8637642B2 (ja) |
EP (3) | EP2621526B1 (ja) |
JP (8) | JP6083871B2 (ja) |
KR (9) | KR20240013851A (ja) |
CN (2) | CN105567717B (ja) |
AU (1) | AU2011312417B2 (ja) |
BR (1) | BR112013007309B1 (ja) |
CA (1) | CA2811644C (ja) |
CY (2) | CY1121023T1 (ja) |
DK (2) | DK2621526T3 (ja) |
EA (2) | EA201790850A1 (ja) |
ES (2) | ES2874306T3 (ja) |
FR (1) | FR22C1050I2 (ja) |
HK (1) | HK1256964A1 (ja) |
HR (1) | HRP20181154T8 (ja) |
HU (3) | HUE038908T2 (ja) |
IL (5) | IL311145A (ja) |
LT (2) | LT2621526T (ja) |
MX (4) | MX347954B (ja) |
NL (1) | NL301198I2 (ja) |
NO (1) | NO2022039I1 (ja) |
PH (1) | PH12017501461A1 (ja) |
PL (2) | PL3409287T3 (ja) |
PT (2) | PT3409287T (ja) |
RS (1) | RS57483B1 (ja) |
SI (2) | SI3409287T1 (ja) |
TW (7) | TW202344270A (ja) |
UA (1) | UA110495C2 (ja) |
WO (1) | WO2012047724A1 (ja) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20240013851A (ko) * | 2010-09-29 | 2024-01-30 | 어젠시스 인코포레이티드 | 191p4d12 단백질에 결합하는 항체 약물 컨쥬게이트(adc) |
US20130058947A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc | Novel Modulators and Methods of Use |
US20130116404A1 (en) | 2011-11-08 | 2013-05-09 | Case Western Reserve University | Targeted non-invasive imaging probes of egfr expressing cells |
EP3539985A1 (en) | 2012-02-24 | 2019-09-18 | AbbVie Stemcentrx LLC | Anti sez6 antibodies and methods of use |
SG11201405131XA (en) | 2012-02-24 | 2014-10-30 | Stemcentrx Inc | Dll3 modulators and methods of use |
SG11201501286PA (en) * | 2012-08-23 | 2015-05-28 | Agensys Inc | Antibody drug conjugates (adc) that bind to 158p1d7 proteins |
WO2014089177A2 (en) | 2012-12-04 | 2014-06-12 | Massachusetts Institute Of Technology | Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines |
EP2954056A4 (en) | 2013-02-08 | 2016-09-21 | Stemcentrx Inc | NEW MULTISPECIFIC CONSTRUCTIONS |
MX2015010682A (es) | 2013-02-22 | 2016-05-31 | Stemcentrx Inc | Nuevos conjugados de anticuerpos y usos de los mismos. |
BR112016004073A8 (pt) * | 2013-08-28 | 2018-06-12 | Stemcentrx Inc | Anticorpos criados por engenharia, conjugados de anticorpo fármaco, seu método de preparação e seu uso, composição farmacêutica e seu uso, kits, e métodos para administrar uma pirrolobenzodiazepina (pbd) a uma célula de câncer que expressa dll3 e para determinar a citotoxicidade de um conjugado de anticorpo fármaco anti-dll3 |
MX2016002547A (es) | 2013-08-28 | 2016-06-17 | Stemcentrx Inc | Metodos de conjugacion de anticuerpos especificos de sitio y composiciones. |
SG11201601416VA (en) | 2013-08-28 | 2016-03-30 | Stemcentrx Inc | Novel sez6 modulators and methods of use |
CR20160437A (es) | 2014-02-21 | 2017-02-20 | Abbvie Stemcentrx Llc | Conjugados de anticuerpos anti-drosophila similar a delta 3 (anti-dll3) y medicamentos para uso en el tratamiento contra melanoma |
SG10201808837RA (en) * | 2014-03-21 | 2018-11-29 | Abbvie Inc | Anti-egfr antibodies and antibody drug conjugates |
CN104212698A (zh) * | 2014-10-01 | 2014-12-17 | 南京飞马食品有限公司 | 一种发芽糙米醋的制作方法 |
WO2016145099A1 (en) | 2015-03-09 | 2016-09-15 | Agensys, Inc. | Antibody drug conjugates (adc) that bind to flt3 proteins |
KR20180021723A (ko) * | 2015-06-29 | 2018-03-05 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 콘주게이트의 선택적 제조 방법 |
EP3347048B1 (en) | 2015-09-09 | 2020-04-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies having specificity to nectin-4 and uses thereof |
WO2017197045A1 (en) | 2016-05-11 | 2017-11-16 | Movassaghi Mohammad | Convergent and enantioselective total synthesis of communesin analogs |
EP3510047A1 (en) | 2016-09-07 | 2019-07-17 | Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. | Anti-nkp46 antibodies and therapeutic use of same |
CN110392697A (zh) | 2017-03-02 | 2019-10-29 | 国家医疗保健研究所 | 对nectin-4具有特异性的抗体及其用途 |
WO2018209239A1 (en) | 2017-05-11 | 2018-11-15 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
WO2018226578A1 (en) * | 2017-06-05 | 2018-12-13 | Agensys, Inc. | Nectin-4-binding proteins and methods of use thereof |
AU2018329937A1 (en) * | 2017-09-07 | 2020-03-19 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and nectin4 |
US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
WO2019183633A1 (en) | 2018-03-23 | 2019-09-26 | Case Western Reserve Univeristy | Psma targeted conjugate compounds and uses thereof |
WO2019183438A1 (en) | 2018-03-23 | 2019-09-26 | Seattle Genetics, Inc. | Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor |
US11180531B2 (en) * | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
CA3121573A1 (en) * | 2018-12-03 | 2020-06-11 | Agensys, Inc. | Pharmaceutical compositions comprising anti-191p4d12 antibody drug conjugates and methods of use thereof |
WO2020247054A1 (en) | 2019-06-05 | 2020-12-10 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
BR112022002391A2 (pt) * | 2019-08-13 | 2022-12-13 | Agensys Inc | Tratamento de câncer com conjugados anticorpo-fármaco (adc) que se ligam às proteínas 191p4d12 |
MX2022006289A (es) * | 2019-11-25 | 2022-06-29 | Agensys Inc | Tratamiento de canceres con conjugados anticuerpo-farmaco (adc) que se unen a las proteinas 191p4d12. |
JP2023512036A (ja) | 2020-01-31 | 2023-03-23 | イナート・ファルマ・ソシエテ・アノニム | 癌の処置 |
EP4106819A1 (en) | 2020-02-21 | 2022-12-28 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
US20230165969A1 (en) * | 2020-03-25 | 2023-06-01 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pharmaceutical composition comprising antibody drug conjugate and use thereof |
CN115955980A (zh) | 2020-04-10 | 2023-04-11 | 思进公司 | 电荷可变接头 |
JP2023540526A (ja) | 2020-09-04 | 2023-09-25 | ノヴァロック バイオセラピューティクス, リミテッド | ネクチン-4抗体およびそれの使用 |
CN116234564A (zh) | 2020-09-16 | 2023-06-06 | 四川科伦博泰生物医药股份有限公司 | 抗Nectin-4抗体、包含所述抗体的缀合物及其应用 |
EP4213888A1 (en) * | 2020-09-17 | 2023-07-26 | Agensys, Inc. | Methods for treating cancers with antibody drug conjugates (adc) that bind to 191p4d12 proteins |
CA3196218A1 (en) | 2020-10-25 | 2022-04-28 | Philipp SPYCHER | Means and methods for producing antibody-linker conjugates |
AU2021376218A1 (en) | 2020-11-08 | 2023-06-15 | Seagen Inc. | Combination Therapy |
KR102408221B1 (ko) * | 2020-11-10 | 2022-06-13 | 삼성메카닉스 (주) | 그리드 커플링 성형장치 |
JP2024501121A (ja) | 2020-11-25 | 2024-01-11 | イナート・ファルマ・ソシエテ・アノニム | 癌の処置 |
EP4086284A1 (en) | 2021-05-07 | 2022-11-09 | Emergence Therapeutics AG | Anti-nectin-4 antibody exatecan conjugates |
BR112023019749A2 (pt) | 2021-03-31 | 2024-01-23 | Centre Nat Rech Scient | Conjugados de exatecano anti-nectina-4, composição farmacêutica que os compreende e seus usos |
CN117279664A (zh) | 2021-04-10 | 2023-12-22 | 普方生物制药美国公司 | Folr1结合剂、其偶联物及其使用方法 |
JP2024516631A (ja) | 2021-04-23 | 2024-04-16 | プロファウンドバイオ ユーエス カンパニー | 抗cd70抗体、そのコンジュゲートおよびこれを使用する方法 |
CN116917324A (zh) | 2021-04-26 | 2023-10-20 | 江苏恒瑞医药股份有限公司 | 抗Nectin-4抗体和抗Nectin-4抗体-药物偶联物及其医药用途 |
EP4346906A1 (en) | 2021-05-28 | 2024-04-10 | Seagen Inc. | Anthracycline antibody conjugates |
IL310175A (en) * | 2021-08-13 | 2024-03-01 | Agensys Inc | Methods for treating non-muscle invasive bladder cancer (NMIBC) with antibody-drug conjugates (ADC) that bind to 191P4D12 proteins |
WO2023092099A1 (en) | 2021-11-19 | 2023-05-25 | Ardeagen Corporation | Gpc3 binding agents, conjugates thereof and methods of using the same |
WO2023178289A2 (en) | 2022-03-17 | 2023-09-21 | Seagen Inc. | Camptothecin conjugates |
WO2023180490A1 (en) | 2022-03-23 | 2023-09-28 | Synaffix B.V. | Antibody-conjugates for targeting of tumours expressing nectin-4 |
WO2023227660A1 (en) | 2022-05-25 | 2023-11-30 | Innate Pharma | Nectin-4 binding agents |
WO2023235754A1 (en) | 2022-06-01 | 2023-12-07 | ALX Oncology Inc. | Combination therapies for treating urothelial carcinoma |
EP4285935A1 (en) | 2022-06-03 | 2023-12-06 | Emergence Therapeutics AG | Novel anti-nectin-4 antibody camptothecin derivative conjugates |
EP4309676A1 (en) | 2022-07-22 | 2024-01-24 | Emergence Therapeutics AG | Novel anti-nectin-4 antibody camptothecin derivative conjugates |
EP4324849A1 (en) | 2022-08-18 | 2024-02-21 | Emergence Therapeutics AG | Humanized anti-nectin-4 antibodies |
WO2024052503A1 (en) | 2022-09-08 | 2024-03-14 | Institut National de la Santé et de la Recherche Médicale | Antibodies having specificity to ltbp2 and uses thereof |
EP4344707A1 (en) | 2022-09-29 | 2024-04-03 | Emergence Therapeutics AG | New anti-nectin-4 antibody drug conjugates |
Family Cites Families (151)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
US4486414A (en) | 1983-03-21 | 1984-12-04 | Arizona Board Of Reagents | Dolastatins A and B cell growth inhibitory substances |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4970198A (en) | 1985-10-17 | 1990-11-13 | American Cyanamid Company | Antitumor antibiotics (LL-E33288 complex) |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
US5079233A (en) | 1987-01-30 | 1992-01-07 | American Cyanamid Company | N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same |
JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
US4816444A (en) | 1987-07-10 | 1989-03-28 | Arizona Board Of Regents, Arizona State University | Cell growth inhibitory substance |
US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
US5053394A (en) | 1988-09-21 | 1991-10-01 | American Cyanamid Company | Targeted forms of methyltrithio antitumor agents |
IL106992A (en) | 1988-02-11 | 1994-06-24 | Bristol Myers Squibb Co | Noble hydrazonic history of anthracycline and methods for their preparation |
US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5076973A (en) | 1988-10-24 | 1991-12-31 | Arizona Board Of Regents | Synthesis of dolastatin 3 |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US4978744A (en) | 1989-01-27 | 1990-12-18 | Arizona Board Of Regents | Synthesis of dolastatin 10 |
US4879278A (en) | 1989-05-16 | 1989-11-07 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15 |
US4986988A (en) | 1989-05-18 | 1991-01-22 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13 |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5138036A (en) | 1989-11-13 | 1992-08-11 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14 |
US6657103B1 (en) | 1990-01-12 | 2003-12-02 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
CA2089661C (en) | 1990-08-29 | 2007-04-03 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
CA2122732C (en) | 1991-11-25 | 2008-04-08 | Marc D. Whitlow | Multivalent antigen-binding proteins |
US5885793A (en) | 1991-12-02 | 1999-03-23 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
CA2118508A1 (en) | 1992-04-24 | 1993-11-11 | Elizabeth S. Ward | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
JP3095175B2 (ja) | 1992-11-13 | 2000-10-03 | アイデック ファーマシューティカルズ コーポレイション | B細胞リンパ腫の治療のためのヒトbリンパ球限定分化抗原に対するキメラ抗体と放射能標識抗体の療法利用 |
US6034065A (en) | 1992-12-03 | 2000-03-07 | Arizona Board Of Regents | Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10 |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US5410024A (en) | 1993-01-21 | 1995-04-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide amides |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
US7625697B2 (en) | 1994-06-17 | 2009-12-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for constructing subarrays and subarrays made thereby |
US5521284A (en) | 1994-08-01 | 1996-05-28 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide amides and esters |
US5530097A (en) | 1994-08-01 | 1996-06-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory peptide amides |
US5504191A (en) | 1994-08-01 | 1996-04-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide methyl esters |
US5554725A (en) | 1994-09-14 | 1996-09-10 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Synthesis of dolastatin 15 |
US5599902A (en) | 1994-11-10 | 1997-02-04 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Cancer inhibitory peptides |
US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
PT871490E (pt) | 1995-12-22 | 2003-07-31 | Bristol Myers Squibb Co | Ligantes de hidrazona ramificada |
US6130237A (en) | 1996-09-12 | 2000-10-10 | Cancer Research Campaign Technology Limited | Condensed N-aclyindoles as antitumor agents |
CA2271234C (en) | 1996-10-15 | 2011-04-26 | The Regents Of The University Of California | Animal models of human prostate cancer progression |
US6653445B1 (en) | 1997-01-21 | 2003-11-25 | Human Genome Sciences, Inc. | Human CCV polypeptides |
US6239104B1 (en) | 1997-02-25 | 2001-05-29 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18 |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
WO1998052976A1 (en) | 1997-05-21 | 1998-11-26 | Biovation Limited | Method for the production of non-immunogenic proteins |
US20030065156A1 (en) | 1997-12-23 | 2003-04-03 | Williams Lewis T. | Novel human genes and gene expression products I |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
ATE342918T1 (de) | 1998-04-15 | 2006-11-15 | Serono Genetics Inst Sa | Genomische sequenz des 5-lipoxygenase- aktivierenden proteins (flap), polymorphische marker und ihre anwendung in der diagnose von asthma |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
US6264949B1 (en) | 1998-09-29 | 2001-07-24 | Mount Sinai School Of Medicine Of New York University | Noninvasive agents for diagnosis and prognosis of the progression of fibrosis |
US20020137160A1 (en) | 1998-12-17 | 2002-09-26 | Byatt John C | Nucleic acid and other molecules associated with lactation and muscle and fat deposition |
US7160694B2 (en) | 1999-06-14 | 2007-01-09 | Millennium Pharmaceuticals, Inc. | Nucleic acids encoding TANGO405 and functional fragments and uses thereof |
AU6069300A (en) | 1999-07-02 | 2001-01-22 | Chiron Corporation | Novel human genes and gene expression products |
EP1074617A3 (en) | 1999-07-29 | 2004-04-21 | Research Association for Biotechnology | Primers for synthesising full-length cDNA and their use |
JP2003533968A (ja) | 1999-09-03 | 2003-11-18 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | 免疫グロブリンスーパーファミリーポリヌクレオチド、ポリペプチド、および抗体 |
WO2001018016A1 (en) | 1999-09-10 | 2001-03-15 | Millennium Pharmaceuticals, Inc. | Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses |
US6323315B1 (en) | 1999-09-10 | 2001-11-27 | Basf Aktiengesellschaft | Dolastatin peptides |
CA2384713A1 (en) | 1999-09-29 | 2001-04-05 | Human Genome Sciences, Inc. | Colon and colon cancer associated polynucleotides and polypeptides |
WO2001051628A2 (en) | 2000-01-14 | 2001-07-19 | Millennium Pharmaceuticals, Inc. | Genes compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
US20030013649A1 (en) | 2000-01-31 | 2003-01-16 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
US20020090672A1 (en) | 2000-01-31 | 2002-07-11 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
WO2001055309A2 (en) | 2000-01-31 | 2001-08-02 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
AU2001243142A1 (en) | 2000-02-03 | 2001-08-14 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
AU2001241541A1 (en) | 2000-02-17 | 2001-08-27 | Millennium Predictive Medicine, Inc. | Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer |
CN1169954C (zh) | 2000-03-09 | 2004-10-06 | 上海市肿瘤研究所 | 编码具有抑制癌细胞生长功能的人蛋白的多核苷酸 |
WO2001070979A2 (en) | 2000-03-21 | 2001-09-27 | Millennium Pharmaceuticals, Inc. | Genes, compositions, kits, and method for identification, assessment, prevention and therapy of ovarian cancer |
US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
AU2001274888A1 (en) | 2000-05-19 | 2001-12-03 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
EP1358349A2 (en) | 2000-06-05 | 2003-11-05 | Avalon Pharmaceuticals | Cancer gene determination and therapeutic screening using signature gene sets |
WO2002010449A2 (en) | 2000-07-28 | 2002-02-07 | Compugen Inc. | Oligonucleotide library for detecting rna transcripts and splice variants that populate a transcriptome |
WO2002028902A2 (en) | 2000-10-05 | 2002-04-11 | Immunex Corporation | Nectin polypeptides, polynucleotides, methods of making and use thereof |
TWI313299B (en) | 2000-11-30 | 2009-08-11 | Medarex Inc | Transgenic transchromosomal rodents for making human antibodies |
CN1297700C (zh) * | 2000-12-20 | 2007-01-31 | 帝人株式会社 | 生产聚酯混合纤维纱的方法 |
US20040029114A1 (en) | 2001-01-24 | 2004-02-12 | Eos Technology, Inc. | Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer |
EP1425302A2 (en) | 2001-01-24 | 2004-06-09 | Protein Design Labs | Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer |
US20030073144A1 (en) | 2001-01-30 | 2003-04-17 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of pancreatic cancer |
US7271240B2 (en) | 2001-03-14 | 2007-09-18 | Agensys, Inc. | 125P5C8: a tissue specific protein highly expressed in various cancers |
WO2002086084A2 (en) | 2001-04-04 | 2002-10-31 | Quark Biotech, Inc. | Sequence characteristics of bladder cancer |
CA2444691A1 (en) | 2001-04-18 | 2002-10-31 | Protein Design Labs, Inc. | Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer |
US20030083263A1 (en) | 2001-04-30 | 2003-05-01 | Svetlana Doronina | Pentapeptide compounds and uses related thereto |
US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
US6794501B2 (en) | 2001-05-04 | 2004-09-21 | Ludwig Institute For Cancer Research | Colon cancer antigen panel |
US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
JP2005505257A (ja) | 2001-06-05 | 2005-02-24 | エクセリクシス・インコーポレイテッド | p53経路のモディファイヤーとしてのIGsおよび使用方法 |
US7171311B2 (en) | 2001-06-18 | 2007-01-30 | Rosetta Inpharmatics Llc | Methods of assigning treatment to breast cancer patients |
WO2002102235A2 (en) | 2001-06-18 | 2002-12-27 | Eos Biotechnology Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
US7189507B2 (en) | 2001-06-18 | 2007-03-13 | Pdl Biopharma, Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
US20040076955A1 (en) | 2001-07-03 | 2004-04-22 | Eos Biotechnology, Inc. | Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer |
US20030099974A1 (en) | 2001-07-18 | 2003-05-29 | Millennium Pharmaceuticals, Inc. | Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of breast cancer |
PL207588B1 (pl) | 2001-07-19 | 2011-01-31 | Nymox Corp | Peptyd NTP, środek zawierający ten peptyd i zastosowanie tego peptydu |
MXPA04002593A (es) | 2001-09-18 | 2004-05-31 | Genentech Inc | Composiciones y metodos para el diagnostico y tratamiento de tumor. |
JP4200100B2 (ja) * | 2001-11-07 | 2008-12-24 | アジェンシス,インコーポレイテッド | 癌の処置および検出において有用な161p2f10bと称される、核酸および対応タンパク質 |
WO2003042661A2 (en) | 2001-11-13 | 2003-05-22 | Protein Design Labs, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
US20030232350A1 (en) | 2001-11-13 | 2003-12-18 | Eos Biotechnology, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
WO2003106635A2 (en) | 2002-06-13 | 2003-12-24 | Regulome Corp | Functional sites |
EP2357006B1 (en) | 2002-07-31 | 2015-09-16 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
WO2004016733A2 (en) * | 2002-08-16 | 2004-02-26 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer |
AU2008202217B2 (en) * | 2002-08-16 | 2012-07-26 | Agensys, Inc. | Nucleic acids and corresponding proteins entitled 191PAD12(b) useful in treatment and detection of cancer |
EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
CA2496923A1 (en) | 2002-08-29 | 2004-03-11 | University Of Massachusetts | Utilization of emulsion interface engineering to produce oxidatively stable lipid delivery systems |
AR045563A1 (es) * | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
EP3120861B1 (en) | 2003-11-06 | 2018-08-15 | Seattle Genetics, Inc. | Intermediate for conjugate preparation comprising auristatin derivatives and a linker |
CA2560919A1 (en) | 2004-03-26 | 2005-10-06 | Pfizer Products Inc. | Uses of anti-ctla-4 antibodies |
EP1747236A1 (en) | 2004-05-12 | 2007-01-31 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Nectin 4(n4) as a marker for cancer prognosis |
RU2402548C2 (ru) | 2004-05-19 | 2010-10-27 | Медарекс, Инк. | Химические линкеры и их конъюгаты |
CA2580141C (en) | 2004-09-23 | 2013-12-10 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
CN101500590A (zh) * | 2005-03-31 | 2009-08-05 | 阿根西斯公司 | 与161p2f10b蛋白结合的抗体和相关分子 |
EP2444099A1 (en) | 2005-03-31 | 2012-04-25 | Agensys, Inc. | Antibodies and related molecules that bind to 161P2F10B proteins |
WO2008007648A1 (fr) * | 2006-07-10 | 2008-01-17 | Institute For Antibodies Co., Ltd. | Procédé de classification d'antigène, procédé d'identification d'antigène, procédé d'obtention d' un ensemble d'antigènes ou d'anticorps, procédés de construction d'un panel d'anticorps, anticorps et ens |
SI2502938T1 (sl) | 2006-10-27 | 2015-05-29 | Genentech, Inc. | Protitelesa in imunokonjugati in njihove uporabe |
JP5394246B2 (ja) | 2007-03-30 | 2014-01-22 | ジェネンテック, インコーポレイテッド | 抗体及びイムノコンジュゲートとこれらの使用方法 |
JP5485897B2 (ja) * | 2007-10-12 | 2014-05-07 | シアトル ジェネティクス,インコーポレーテッド | 抗体−薬物複合体の併用療法 |
KR20240013851A (ko) * | 2010-09-29 | 2024-01-30 | 어젠시스 인코포레이티드 | 191p4d12 단백질에 결합하는 항체 약물 컨쥬게이트(adc) |
-
2011
- 2011-09-29 KR KR1020247001866A patent/KR20240013851A/ko not_active Application Discontinuation
- 2011-09-29 CA CA2811644A patent/CA2811644C/en active Active
- 2011-09-29 KR KR1020237006492A patent/KR102595129B1/ko active IP Right Grant
- 2011-09-29 JP JP2013531875A patent/JP6083871B2/ja active Active
- 2011-09-29 TW TW112112533A patent/TW202344270A/zh unknown
- 2011-09-29 KR KR1020197004139A patent/KR102166408B1/ko active IP Right Grant
- 2011-09-29 DK DK11831345.1T patent/DK2621526T3/en active
- 2011-09-29 CN CN201510519846.0A patent/CN105567717B/zh active Active
- 2011-09-29 ES ES18171803T patent/ES2874306T3/es active Active
- 2011-09-29 PT PT181718032T patent/PT3409287T/pt unknown
- 2011-09-29 BR BR112013007309-8A patent/BR112013007309B1/pt active IP Right Grant
- 2011-09-29 PL PL18171803T patent/PL3409287T3/pl unknown
- 2011-09-29 TW TW109135992A patent/TWI764324B/zh active
- 2011-09-29 TW TW107103146A patent/TWI674112B/zh active
- 2011-09-29 EP EP11831345.1A patent/EP2621526B1/en active Active
- 2011-09-29 PL PL11831345T patent/PL2621526T3/pl unknown
- 2011-09-29 SI SI201131986T patent/SI3409287T1/sl unknown
- 2011-09-29 WO PCT/US2011/054054 patent/WO2012047724A1/en active Application Filing
- 2011-09-29 EP EP18171803.2A patent/EP3409287B9/en active Active
- 2011-09-29 IL IL311145A patent/IL311145A/en unknown
- 2011-09-29 US US13/249,111 patent/US8637642B2/en not_active Ceased
- 2011-09-29 AU AU2011312417A patent/AU2011312417B2/en active Active
- 2011-09-29 TW TW100135340A patent/TWI524901B/zh active
- 2011-09-29 MX MX2016003743A patent/MX347954B/es unknown
- 2011-09-29 KR KR1020237028203A patent/KR102627947B1/ko active IP Right Grant
- 2011-09-29 IL IL290591A patent/IL290591B1/en unknown
- 2011-09-29 PT PT118313451T patent/PT2621526T/pt unknown
- 2011-09-29 TW TW111117461A patent/TWI814373B/zh active
- 2011-09-29 KR KR1020217026806A patent/KR102353283B1/ko active IP Right Grant
- 2011-09-29 EP EP21166650.8A patent/EP3903812A1/en active Pending
- 2011-09-29 HU HUE11831345A patent/HUE038908T2/hu unknown
- 2011-09-29 RS RS20180854A patent/RS57483B1/sr unknown
- 2011-09-29 TW TW104140581A patent/TWI651096B/zh active
- 2011-09-29 CN CN201180056969.5A patent/CN103402538B/zh active Active
- 2011-09-29 KR KR1020177031187A patent/KR101851746B1/ko active IP Right Grant
- 2011-09-29 TW TW107143990A patent/TWI720377B/zh active
- 2011-09-29 MX MX2013003419A patent/MX337873B/es active IP Right Grant
- 2011-09-29 EA EA201790850A patent/EA201790850A1/ru unknown
- 2011-09-29 EA EA201300411A patent/EA027887B1/ru unknown
- 2011-09-29 LT LTEP11831345.1T patent/LT2621526T/lt unknown
- 2011-09-29 HU HUE18171803A patent/HUE054855T2/hu unknown
- 2011-09-29 DK DK18171803.2T patent/DK3409287T5/da active
- 2011-09-29 KR KR1020207028941A patent/KR102295534B1/ko active IP Right Grant
- 2011-09-29 KR KR1020137011094A patent/KR20130130709A/ko active Application Filing
- 2011-09-29 SI SI201131535T patent/SI2621526T1/sl unknown
- 2011-09-29 UA UAA201305358A patent/UA110495C2/uk unknown
- 2011-09-29 MX MX2017006479A patent/MX369679B/es unknown
- 2011-09-29 ES ES11831345.1T patent/ES2680624T3/es active Active
- 2011-09-29 KR KR1020227001399A patent/KR102504750B1/ko active IP Right Grant
-
2013
- 2013-03-14 US US13/830,899 patent/US9078931B2/en active Active
- 2013-03-22 MX MX2019013655A patent/MX2019013655A/es unknown
- 2013-03-24 IL IL225460A patent/IL225460B/en active IP Right Grant
-
2015
- 2015-07-13 US US14/798,302 patent/US9314538B2/en active Active
-
2016
- 2016-03-14 US US15/069,853 patent/US9962454B2/en active Active
- 2016-12-15 JP JP2016243252A patent/JP2017110002A/ja not_active Withdrawn
-
2017
- 2017-08-14 PH PH12017501461A patent/PH12017501461A1/en unknown
- 2017-09-06 US US15/697,146 patent/USRE48389E1/en active Active
-
2018
- 2018-04-02 US US15/943,527 patent/US10894090B2/en active Active
- 2018-07-23 HR HRP20181154TT patent/HRP20181154T8/hr unknown
- 2018-07-31 CY CY181100790T patent/CY1121023T1/el unknown
- 2018-10-02 IL IL262073A patent/IL262073B/en active IP Right Grant
- 2018-11-02 JP JP2018207426A patent/JP6726258B2/ja active Active
- 2018-11-02 JP JP2018207044A patent/JP2019055958A/ja active Pending
- 2018-11-02 JP JP2018207295A patent/JP2019031563A/ja active Pending
- 2018-12-14 HK HK18116104.9A patent/HK1256964A1/zh unknown
-
2020
- 2020-06-26 JP JP2020110083A patent/JP7042872B2/ja active Active
- 2020-11-13 IL IL278696A patent/IL278696B/en unknown
- 2020-12-15 US US17/122,786 patent/US11559582B2/en active Active
-
2021
- 2021-05-18 CY CY20211100429T patent/CY1124166T1/el unknown
-
2022
- 2022-03-15 JP JP2022039841A patent/JP7370405B2/ja active Active
- 2022-09-28 NL NL301198C patent/NL301198I2/nl unknown
- 2022-09-29 NO NO2022039C patent/NO2022039I1/no unknown
- 2022-10-04 HU HUS2200043C patent/HUS2200043I1/hu unknown
- 2022-10-05 FR FR22C1050C patent/FR22C1050I2/fr active Active
- 2022-10-05 LT LTPA2022012C patent/LTPA2022012I1/lt unknown
- 2022-12-14 US US18/066,156 patent/US20230346968A1/en active Pending
-
2023
- 2023-10-17 JP JP2023178591A patent/JP2023179713A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2020152735A5 (ja) | ||
JP2023179713A5 (ja) | ||
JP2022075818A5 (ja) | ||
JP2019031565A5 (ja) | ||
JP2017110002A5 (ja) | ||
IL262073A (en) | Antibodies associated with p4d12191, preparations containing them and uses | |
IL268745A (en) | Antibody and drug (ADC) linkages that bind to 158P1D7 proteins | |
JP2017514461A5 (ja) | ||
JP2017534256A5 (ja) | ||
JP2017500028A5 (ja) | ||
IL302078A (en) | Anti-CCR8 monoclonal antibodies and their uses | |
JP2015509947A5 (ja) | ||
JP2018505177A5 (ja) | ||
HRP20160082T1 (hr) | Sastavi i postupci za dijagnosticiranje i lijeäśenje raka | |
JP2017529838A5 (ja) | ||
JP2015533781A5 (ja) | ||
JP2013543498A5 (ja) | ||
RU2011103125A (ru) | КОМБИНАЦИЯ АНТАГОНИСТА c-Met И АМИНОГЕТЕРОАРИЛА ДЛЯ ЛЕЧЕНИЯ РАКА | |
JP2016536020A5 (ja) | ||
RU2009120052A (ru) | Композиции и способы связывания сфингозин-1-фосфата | |
JP2010516229A5 (ja) | ||
JP2023070678A5 (ja) | ||
JP2014511179A5 (ja) | ||
JP2008537673A5 (ja) | ||
RU2009129403A (ru) | Антитела, нейтрализующие цитомегаловирус человека, и их применение |